


In the Specification:

Please replace the paragraph beginning at page 4, line 16, with the following:



~~pan~~ DR peptides can be described using various conventions. For example, preferred pan DR peptides have the formula $R_1-R_2-R_3-R_4-R_5$, proceeding in the direction from the amino-terminus of the peptide (R_1) to the carboxy-terminus (R_5), where R_1 is a D-amino acid followed by alanine or lysine; R_2 is cyclohexylalanine, tyrosine, or phenylalanine; R_3 is 3 or 4 amino acids each of which is independently selected from the group consisting of alanine, isoleucine, serine and valine; R_4 is threonine-leucine-lysine, lysine-threonine, or tryptophan-threonine-leucine-lysine (SEQ ID NO:16); and R_5 consists of 2 to 4 amino acids followed by a D-amino acid, where each of the 2 or 4 amino acids is independently selected from the group consisting of alanine, serine and valine. According ~~According~~ to this formula, more preferred pan DR peptides have the formula $R_1-R_2-R_3-R_4-R_5$, where R_1 is D-alanine followed by alanine or lysine; R_2 is cyclohexylalanine or phenylalanine; R_3 is 3 or 4 amino acids each of which is selected from the group comprising alanine, isoleucine, and valine; R_4 is threonine-leucine-lysine, lysine-threonine, or tryptophan-threonine-leucine-lysine; and R_5 is 2 to 4 alanines followed by D-alanine.

Please replace the paragraph (TABLE I) beginning at page 8, line 1, with the following:

TABLE I

Allele	Assay standard	Sequence	SEQ ID NO:	Avg. IC ₅₀ (nM)
DR1	HA 307-319	PKYVKQNTLKLAT	1	5
DR2w2b	MBP 78-101	GRTQDENPVWHFFKNIVTPRTPPP	2	9.1
DR3	MT 65 kd 3-13	YKTIAFDEEARR	3	250
DR4w4	HA 307-319	PKYVKQNTLKLAT	1	45
DR4w14	717.01 combinatorial	YARFQSQTTLKQKT	4	50
DR5	Tet Tox 830-843	QYIKANSKFIGITE	5	20
DR7	Tet Tox 830-843	QYIKANSKFIGITE	5	25
DR52a	Tet Tox 1272-1284	NGQIGNDPNRDIL	6	470
DRw53	717.01 combinatorial	YARFQSQTTLKQKT	4	58
Dr2w2a	Tet Tox 830-843	QYIKANSKFIGITE	5	20
DQ3.1	ROIV	YAHAAHAAHAAHAAHAA	7	15
IAb	ROIV	YAHAAHAAHAAHAAHAA	7	28
IAd	Ova 323-336	ISQAVHAAHAEINE	8	110
IEd	lambda rep 12-26	YLEDARRLKAIYEKKK	9	170
IAS	ROIV	YAHAAHAAHAAHAAHAA	7	54
IAk	HEL 46-61	YNTDGSTDYGILQINSR	10	20
IEk	lambda rep 12-26	YLEDARRLKAIYEKKK	9	28

Please replace the paragraph (Table II) beginning at page 36, line 1, with the following (see attached sheet).

Please replace the paragraph (Table III) beginning at page 39, line 1, with the following (see attached sheet).

Please insert the accompanying paper copy of the Sequence Listing, page numbers 1 to 8, at the end of the application.